Halmos Labs, a new biotech startup based in Lund, has joined Y Combinator’s fall 2026 batch, and thereby also secured $500K in first funding.
Halmos Labs builds automated biotech R&D on the principles of validity and interpretabillity. They run research, and simulations answering open questions ranging from wetlab experiment design to full cancer vaccine manufacturing.
While the company itself is named Halmos Labs, its first product will be called Halmos Bio, founder Mattias Akke tells Swedish Tech News which was first with reporting the news.
The founders, Mattias Akke and Linus von Ekensteen Löfgren, have a background in Nanotechnology and Engineering Physics, and previous experience from MIT, AstraZenica, and Danske Bank.
